PHARMA MAR, S.A. from 14/11/2018 to 14/11/2018 The price-sensitive information presented in other languages is a literal translation of the price-sensitive information stated in Spanish 14/11/2018 15:12 PHARMA MAR, S.A. R&D: new licenses, patents and registered trademarks 100 patients have been already recruited in the Phase II clinical trial of lurbinectedin as a single agent in recurrent small cell lung cancer. Register number: 271525